METHOD FOR TRANSMITTING DATA IN A BLOOD GLUCOSE SYSTEM AND CORRESPONDING BLOOD GLUCOSE SYSTEM
First Claim
1. A method for wireless transmission of data between components of a blood glucose system including a master controller having a receiver and a transmitter, and a slave device comprising an insulin dispensing means and having a receiver and a transmitter, the method comprises the following steps:
- operating the slave device normally in a power saving mode in which its receiver is activated intermittently at a receiver activation frequency, with the receiver each time being activated for a predetermined listening period and the receiver being deactivated for the rest of the time,activating the transmitter of the controller for a transmission period to transmit a communication initiation data frame including a preamble portion which is chosen such that a preamble signal is transmitted for a preamble period, and subsequently activating the receiver of the controller for a response period, andin case the slave device receives the preamble signal during a listening period,a) maintaining the receiver of the slave device active until at least a portion of the remainder of the communication initiation data frame has been received,b) switching the slave device to a communication mode in which the transmitter of the slave device is activated to transmit a response to the controller, andc) switching the slave device from the communication mode to the power saving mode,initially setting the receiver activation frequency to a first frequency value upon switching from communication mode to power saving mode, and setting the receiver activation frequency to a second frequency value smaller than the first frequency value if no communication initiation data frame is received for a predetermined power saving timeout period, whereinthe communication initiation data frame is transmitted such that the preamble period exceeds the length of the cycle duration corresponding to the first frequency value, and, in case no response is received by the controller during the response period, the communication initiation data frame is adapted and retransmitted such that the preamble period is increased and exceeds the length of the cycle duration corresponding to the second frequency value.
5 Assignments
0 Petitions

Accused Products

Abstract
The present invention relates to a method for wireless transmission of data between components of a blood glucose system (1, I1) including a master controller (2, 2′) having a receiver (10) and a transmitter (9), and at least one slave device (3) having a receiver (19) and a transmitter (18), and to a corresponding blood glucose system (1, I1). The slave device (3) is normally operated in a power saving mode in which its receiver (19) is only activated intermittently at a receiver activation frequency for a predetermined listening period. The controller (2, 21) transmits a communication initiation data frame to the slave device (3) by means of a signal comprising a preamble signal transmitted for a preamble period. Upon receipt of the communication initiation data frame, the slave device (3) is switched to a communication mode in which it transmits a response to the controller (2, 21), and the slave device (3) is switched from the communication mode to the power saving mode. Initially the receiver activation frequency is set to a first frequency value upon switching from communication mode to power saving mode, and then to a second frequency value smaller than the first frequency value if no communication initiation data frame is received for a predetermined power saving timeout period. The communication initiation data frame is transmitted such that the preamble period exceeds the length of the cycle duration corresponding to the first frequency value, and, in case no response is received by the controller during the response period, the communication initiation data frame is adapted and retransmitted such that the preamble period is increased and exceeds the length of the cycle duration corresponding to the second frequency value.
385 Citations
Analyte monitoring device and methods of use | ||
Patent #
US 7,885,699 B2
Filed 08/06/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge | ||
Patent #
US 7,909,775 B2
Filed 06/26/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,914,465 B2
Filed 02/08/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,909,774 B2
Filed 02/13/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for body fluid sampling and analyte sensing | ||
Patent #
US 7,892,183 B2
Filed 07/03/2003
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Analyte Monitoring System and Methods for Managing Power and Noise | ||
Patent #
US 20110054282A1
Filed 08/31/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for automatically launching applications residing on USB flash drives | ||
Patent #
US 7,865,351 B2
Filed 12/30/2007
|
Current Assignee
Western Digital Israel Limited
|
Original Assignee
Sandisk China Limited
|
Method and apparatus for a multi-use body fluid sampling device with sterility barrier release | ||
Patent #
US 7,875,047 B2
Filed 01/25/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,909,778 B2
Filed 04/20/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,909,777 B2
Filed 09/29/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Analyte monitoring device and methods of use | ||
Patent #
US 7,869,853 B1
Filed 08/06/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,901,365 B2
Filed 03/21/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,938,787 B2
Filed 09/29/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Analyte monitoring system and method | ||
Patent #
US 7,920,907 B2
Filed 06/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transmitting Instructions in a Medical Supply Unit | ||
Patent #
US 20110118879A1
Filed 11/16/2010
|
Current Assignee
Trumpf Medizin Systeme GmbH Co. KG
|
Original Assignee
Trumpf Medizin Systeme GmbH Co. KG
|
ZIGBEE GATEWAY AND MESSAGE IDENTIFICATION METHOD OF THE SAME | ||
Patent #
US 20110149932A1
Filed 09/22/2010
|
Current Assignee
Electronics and Telecommunications Research Institute
|
Original Assignee
Electronics and Telecommunications Research Institute
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,959,582 B2
Filed 03/21/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,007,446 B2
Filed 10/19/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for a multi-use body fluid sampling device with sterility barrier release | ||
Patent #
US 7,988,644 B2
Filed 03/21/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Tissue penetration device | ||
Patent #
US 8,016,774 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Methods and apparatus for lancet actuation | ||
Patent #
US 7,981,056 B2
Filed 06/18/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Device and method for variable speed lancet | ||
Patent #
US 7,976,476 B2
Filed 03/16/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Tissue penetration device | ||
Patent #
US 7,981,055 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties | ||
Patent #
US 7,988,645 B2
Filed 05/03/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,062,231 B2
Filed 10/11/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and System for Transmitting a Signal Comprising Preamble and a Data Frame | ||
Patent #
US 20090122735A1
Filed 09/12/2006
|
Current Assignee
Orange S.A.
|
Original Assignee
Orange S.A.
|
Analyte Monitoring Device and Methods of Use | ||
Patent #
US 20090182212A1
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
DEVICE AND METHOD FOR AUTOMATICALLY LAUNCHING APPLICATIONS RESIDING ON USB FLASH DRIVES | ||
Patent #
US 20090172219A1
Filed 12/30/2007
|
Current Assignee
Western Digital Israel Limited
|
Original Assignee
Sandisk China Limited
|
AUTOMATED TASK EXECUTION FOR AN ANALYTE MONITORING SYSTEM | ||
Patent #
US 20090300616A1
Filed 05/30/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge | ||
Patent #
US 8,123,700 B2
Filed 06/26/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Methods and apparatus for lancet actuation | ||
Patent #
US 8,079,960 B2
Filed 10/10/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Methods and apparatus for lancet actuation | ||
Patent #
US 8,157,748 B2
Filed 01/10/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,162,829 B2
Filed 03/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 8,162,853 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,175,673 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,177,716 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,197,421 B2
Filed 07/16/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,197,423 B2
Filed 12/14/2010
|
Current Assignee
Pelikan Technologies Inc.
|
Original Assignee
Pelikan Technologies Inc.
|
Tissue penetration device | ||
Patent #
US 8,206,317 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,206,319 B2
Filed 08/26/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,211,037 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Tissue penetration device | ||
Patent #
US 8,216,154 B2
Filed 12/23/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,221,334 B2
Filed 12/22/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,224,413 B2
Filed 10/10/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,558 B2
Filed 09/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,557 B2
Filed 12/28/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,555 B2
Filed 03/18/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,231,532 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,235,896 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,235,915 B2
Filed 12/18/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for body fluid sampling and analyte sensing | ||
Patent #
US 8,251,921 B2
Filed 06/10/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,255,031 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,260,392 B2
Filed 06/09/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for fluid injection | ||
Patent #
US 8,262,614 B2
Filed 06/01/2004
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Pelikan Technologies Inc.
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,265,726 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for body fluid sampling with hybrid actuation | ||
Patent #
US 8,267,870 B2
Filed 05/30/2003
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,273,022 B2
Filed 02/13/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,275,439 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for an improved sample capture device | ||
Patent #
US 8,282,576 B2
Filed 09/29/2004
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge | ||
Patent #
US 8,282,577 B2
Filed 06/15/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,287,454 B2
Filed 09/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method of manufacturing a fluid sampling device with improved analyte detecting member configuration | ||
Patent #
US 8,296,918 B2
Filed 08/23/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,306,598 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 8,333,710 B2
Filed 10/05/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,337,421 B2
Filed 12/16/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,337,419 B2
Filed 10/04/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,337,420 B2
Filed 03/24/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,343,075 B2
Filed 12/23/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,346,336 B2
Filed 03/18/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,346,337 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,353,829 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,357,091 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 8,360,991 B2
Filed 12/23/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,360,992 B2
Filed 11/25/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring system and methods | ||
Patent #
US 8,362,904 B2
Filed 04/18/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,366,637 B2
Filed 12/03/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,366,614 B2
Filed 03/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for body fluid sampling and analyte sensing | ||
Patent #
US 8,372,016 B2
Filed 09/30/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,372,005 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,380,273 B2
Filed 04/11/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,382,682 B2
Filed 02/06/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,382,683 B2
Filed 03/07/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for multi-use body fluid sampling device with sterility barrier release | ||
Patent #
US 8,388,551 B2
Filed 05/27/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,391,945 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,403,864 B2
Filed 05/01/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,409,131 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and apparatus for lancet actuation | ||
Patent #
US 8,414,503 B2
Filed 03/16/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for a multi-use body fluid sampling device with sterility barrier release | ||
Patent #
US 8,430,828 B2
Filed 01/26/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,435,190 B2
Filed 01/19/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and system for transferring analyte test data | ||
Patent #
US 8,437,966 B2
Filed 11/20/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Apparatus and method for penetration with shaft having a sensor for sensing penetration depth | ||
Patent #
US 8,439,872 B2
Filed 04/26/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring system and methods | ||
Patent #
US 8,456,301 B2
Filed 05/08/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,461,985 B2
Filed 05/08/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,465,425 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,473,021 B2
Filed 07/31/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte monitoring system calibration accuracy | ||
Patent #
US 8,478,557 B2
Filed 07/30/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,480,580 B2
Filed 04/19/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for transferring analyte test data | ||
Patent #
US 8,483,974 B2
Filed 11/20/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and apparatus for lancet actuation | ||
Patent #
US 8,491,500 B2
Filed 04/16/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Methods and apparatus for lancet actuation | ||
Patent #
US 8,496,601 B2
Filed 04/16/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Close proximity communication device and methods | ||
Patent #
US 8,509,107 B2
Filed 11/01/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,556,829 B2
Filed 01/27/2009
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,560,038 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for transferring analyte test data | ||
Patent #
US 8,560,250 B2
Filed 08/18/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Laboratories Incorporated
|
Tissue penetration device | ||
Patent #
US 8,562,545 B2
Filed 12/16/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,571,808 B2
Filed 01/23/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for a multi-use body fluid sampling device with analyte sensing | ||
Patent #
US 8,574,168 B2
Filed 03/26/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus using optical techniques to measure analyte levels | ||
Patent #
US 8,574,895 B2
Filed 12/30/2003
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,579,831 B2
Filed 10/06/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 8,585,591 B2
Filed 07/10/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,593,287 B2
Filed 07/20/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 8,593,109 B2
Filed 11/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Health management devices and methods | ||
Patent #
US 8,597,188 B2
Filed 06/20/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,597,189 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 8,597,575 B2
Filed 07/23/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,612,159 B2
Filed 02/16/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,612,163 B2
Filed 08/30/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Health monitor | ||
Patent #
US 8,617,069 B2
Filed 06/20/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,617,071 B2
Filed 06/21/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 8,622,930 B2
Filed 07/18/2011
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,622,906 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable rate closed loop control and methods | ||
Patent #
US 8,622,988 B2
Filed 08/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,202,231 B2
Filed 04/23/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,636,673 B2
Filed 12/01/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,641,619 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sampling module device and method | ||
Patent #
US 8,641,643 B2
Filed 04/27/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means | ||
Patent #
US 8,641,644 B2
Filed 04/23/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,649,841 B2
Filed 04/03/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,652,043 B2
Filed 07/20/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,660,627 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,666,469 B2
Filed 11/16/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,668,645 B2
Filed 01/03/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for improving fluidic flow and sample capture | ||
Patent #
US 8,668,656 B2
Filed 12/31/2004
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and system for transmitting a signal comprising preamble and a data frame | ||
Patent #
US 8,670,360 B2
Filed 09/12/2006
|
Current Assignee
Orange S.A.
|
Original Assignee
Orange S.A.
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,670,815 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,672,844 B2
Filed 02/27/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 8,679,033 B2
Filed 06/16/2011
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,682,615 B2
Filed 08/04/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for transferring analyte test data | ||
Patent #
US 8,682,598 B2
Filed 08/27/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Laboratories Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,688,188 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,690,796 B2
Filed 09/29/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for analyte measurement test time | ||
Patent #
US 8,652,831 B2
Filed 03/26/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte measurement device with a single shot actuator | ||
Patent #
US 8,702,624 B2
Filed 01/29/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Mitigating single point failure of devices in an analyte monitoring system and methods thereof | ||
Patent #
US 8,710,993 B2
Filed 11/21/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte monitoring system calibration accuracy | ||
Patent #
US 8,718,965 B2
Filed 06/24/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Electric lancet actuator | ||
Patent #
US 8,721,671 B2
Filed 07/06/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,734,348 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control with improved alarm functions | ||
Patent #
US 8,734,422 B2
Filed 08/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,734,346 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Close proximity communication device and methods | ||
Patent #
US 8,737,259 B2
Filed 08/05/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,738,109 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,744,545 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
WIRELESS COMMUNICATION AUTHENTICATION FOR MEDICAL MONITORING DEVICE | ||
Patent #
US 20140176338A1
Filed 12/20/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 8,771,183 B2
Filed 02/16/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,774,887 B2
Filed 03/24/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Body fluid sampling device with a capacitive sensor | ||
Patent #
US 8,784,335 B2
Filed 07/25/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Robust closed loop control and methods | ||
Patent #
US 8,795,252 B2
Filed 10/16/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Real time management of data relating to physiological control of glucose levels | ||
Patent #
US 8,798,934 B2
Filed 07/23/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and apparatus for penetrating tissue | ||
Patent #
US 8,808,201 B2
Filed 01/15/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Transmitting instructions in a medical supply unit | ||
Patent #
US 8,810,357 B2
Filed 11/16/2010
|
Current Assignee
Trumpf Medizin Systeme GmbH Co. KG
|
Original Assignee
Trumpf Medizin Systeme GmbH Co. KG
|
Printable hydrogels for biosensors | ||
Patent #
US 8,828,203 B2
Filed 05/20/2005
|
Current Assignee
Sanofi-Aventis SA
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for providing analyte sensor calibration | ||
Patent #
US 8,834,366 B2
Filed 07/31/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,840,553 B2
Filed 02/26/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method for penetrating tissue | ||
Patent #
US 8,845,549 B2
Filed 12/02/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,845,550 B2
Filed 12/03/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,880,137 B2
Filed 04/18/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device for channeling fluid and methods of use | ||
Patent #
US 8,880,138 B2
Filed 09/30/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Infusion pump with blood glucose alert delay | ||
Patent #
US 20140350371A1
Filed 08/08/2014
|
Current Assignee
Tandem Diabetes Care Incorporated
|
Original Assignee
Tandem Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,905,945 B2
Filed 03/29/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Don Alden, Dirk Boecker, Dominique M. Freeman
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,915,850 B2
Filed 03/28/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,920,319 B2
Filed 12/28/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 8,933,664 B2
Filed 11/25/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in integrated analyte monitoring and infusion system | ||
Patent #
US 8,932,216 B2
Filed 08/07/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and Medical Device for Adjusting Dose of Fluid Medicament | ||
Patent #
US 20150025493A1
Filed 11/21/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for an improved sample capture device | ||
Patent #
US 8,945,910 B2
Filed 06/19/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,965,476 B2
Filed 04/18/2011
|
Current Assignee
Pelikan Technologies Inc.
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
COORDINATION OF CONTROL COMMANDS IN A MEDICAL DEVICE SYSTEM BASED ON SYNCHRONIZATION STATUS BETWEEN DEVICES | ||
Patent #
US 20150065989A1
Filed 11/10/2014
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,974,386 B2
Filed 11/01/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor sensitivity attenuation mitigation | ||
Patent #
US 8,986,208 B2
Filed 09/30/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods for managing power and noise | ||
Patent #
US 8,993,331 B2
Filed 08/31/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 9,000,929 B2
Filed 11/22/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 9,008,743 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,011,332 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,011,331 B2
Filed 12/29/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,014,773 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors and methods of use | ||
Patent #
US 9,031,630 B2
Filed 11/01/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus using optical techniques to measure analyte levels | ||
Patent #
US 9,034,639 B2
Filed 06/26/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring system and methods | ||
Patent #
US 9,035,767 B2
Filed 05/30/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 9,039,975 B2
Filed 12/02/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,042,953 B2
Filed 03/02/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,060,719 B2
Filed 12/13/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,695 B2
Filed 04/12/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,697 B2
Filed 10/27/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Electronic devices having integrated reset systems and methods thereof | ||
Patent #
US 9,069,536 B2
Filed 10/30/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,694 B2
Filed 04/03/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,072,477 B2
Filed 06/21/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,072,842 B2
Filed 07/31/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,078,607 B2
Filed 06/17/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 9,088,452 B2
Filed 01/31/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte measurement device with a single shot actuator | ||
Patent #
US 9,089,294 B2
Filed 01/16/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,089,678 B2
Filed 05/21/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for providing rolling data in communication systems | ||
Patent #
US 9,095,290 B2
Filed 02/27/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,125,548 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Low pain penetrating member | ||
Patent #
US 9,144,401 B2
Filed 12/12/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring system and methods | ||
Patent #
US 9,177,456 B2
Filed 06/10/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Close proximity communication device and methods | ||
Patent #
US 9,184,875 B2
Filed 04/25/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,186,468 B2
Filed 01/14/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 9,204,827 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Body fluid sampling module with a continuous compression tissue interface surface | ||
Patent #
US 9,226,699 B2
Filed 11/09/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Error detection in critical repeating data in a wireless sensor system | ||
Patent #
US 9,226,701 B2
Filed 04/28/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 9,248,267 B2
Filed 07/18/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Printable hydrogel for biosensors | ||
Patent #
US 9,261,476 B2
Filed 04/01/2014
|
Current Assignee
Sanofi-Aventis SA
|
Original Assignee
Sanofi S.A.
|
Mitigating single point failure of devices in an analyte monitoring system and methods thereof | ||
Patent #
US 9,289,179 B2
Filed 04/11/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 9,314,194 B2
Filed 01/11/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring system and methods | ||
Patent #
US 9,314,198 B2
Filed 04/03/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte signal processing device and methods | ||
Patent #
US 9,314,195 B2
Filed 08/31/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 9,323,898 B2
Filed 11/15/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor with time lag compensation | ||
Patent #
US 9,320,468 B2
Filed 06/21/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
On-body medical device securement | ||
Patent #
US 9,326,727 B2
Filed 05/15/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,326,716 B2
Filed 12/05/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,326,714 B2
Filed 06/29/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor with lag compensation | ||
Patent #
US 9,332,934 B2
Filed 02/08/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 9,339,612 B2
Filed 12/16/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Wireless communication authentication for medical monitoring device | ||
Patent #
US 9,344,777 B2
Filed 12/20/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for a variable user interface | ||
Patent #
US 9,351,680 B2
Filed 10/14/2004
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and system for dynamically updating calibration parameters for an analyte sensor | ||
Patent #
US 9,357,959 B2
Filed 08/19/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Cam drive for managing disposable penetrating member actions with a single motor and motor and control system | ||
Patent #
US 9,375,169 B2
Filed 01/29/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and system for powering an electronic device | ||
Patent #
US 9,380,971 B2
Filed 12/05/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for analyte detecting device | ||
Patent #
US 9,386,944 B2
Filed 04/10/2009
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Closed loop control and signal attenuation detection | ||
Patent #
US 9,392,969 B2
Filed 08/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte sensor calibration | ||
Patent #
US 9,398,872 B2
Filed 08/28/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
TECHNIQUES FOR MANAGING HETEROGENOUS NODES CONFIGURED TO SUPPORT A HOMOGENEOUS COMMUNICATION PROTOCOL | ||
Patent #
US 20160227543A1
Filed 01/28/2016
|
Current Assignee
Itron Networked Solutions Inc.
|
Original Assignee
Silver Spring Networks Inc.
|
Method and system for providing calibration of an analyte sensor in an analyte monitoring system | ||
Patent #
US 9,408,566 B2
Filed 02/13/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 9,427,532 B2
Filed 09/29/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Assessing measures of glycemic variability | ||
Patent #
US 9,439,586 B2
Filed 03/29/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Electronic devices having integrated reset systems and methods thereof | ||
Patent #
US 9,465,420 B2
Filed 06/26/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,483,608 B2
Filed 05/20/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,498,159 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method for penetrating tissue | ||
Patent #
US 9,498,160 B2
Filed 09/29/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Coordination of control commands and controller disable messages in a medical device system | ||
Patent #
US 9,517,304 B2
Filed 11/10/2014
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same | ||
Patent #
US 9,532,737 B2
Filed 02/28/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 9,541,556 B2
Filed 11/25/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for determining analyte levels | ||
Patent #
US 9,558,325 B2
Filed 06/24/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means | ||
Patent #
US 9,560,993 B2
Filed 12/20/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for improving fluidic flow and sample capture | ||
Patent #
US 9,561,000 B2
Filed 12/10/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Robust closed loop control and methods | ||
Patent #
US 9,572,934 B2
Filed 08/01/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for determining elapsed sensor life | ||
Patent #
US 9,574,914 B2
Filed 03/03/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Coordination of control commands in a medical device system based on synchronization status between devices | ||
Patent #
US 9,579,454 B2
Filed 11/10/2014
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,610,034 B2
Filed 11/09/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control with improved alarm functions | ||
Patent #
US 9,610,046 B2
Filed 04/29/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 9,615,780 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 9,625,413 B2
Filed 05/19/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for dynamically updating calibration parameters for an analyte sensor | ||
Patent #
US 9,629,578 B2
Filed 03/26/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Pump system modular components for delivering medication and analyte sensing at seperate insertion sites | ||
Patent #
US 9,636,450 B2
Filed 02/15/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Udo Hoss, Gary A. Stafford
|
Analyte monitoring system and methods | ||
Patent #
US 9,649,057 B2
Filed 05/11/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 9,669,162 B2
Filed 03/16/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 9,693,688 B2
Filed 07/16/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sampling module device and method | ||
Patent #
US 9,694,144 B2
Filed 12/03/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and system for providing data management in integrated analyte monitoring and infusion system | ||
Patent #
US 9,697,332 B2
Filed 12/08/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and medical device for adjusting dose of fluid medicament | ||
Patent #
US 9,707,345 B2
Filed 11/21/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof | ||
Patent #
US 9,721,063 B2
Filed 03/09/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,724,021 B2
Filed 12/08/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Glucose measuring device for use in personal area network | ||
Patent #
US 9,730,584 B2
Filed 02/10/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor calibration management | ||
Patent #
US 9,730,623 B2
Filed 02/05/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,737,249 B2
Filed 06/17/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 9,743,863 B2
Filed 06/01/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Assessing measures of glycemic variability | ||
Patent #
US 9,743,865 B2
Filed 06/25/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Mitigating single point failure of devices in an analyte monitoring system and methods thereof | ||
Patent #
US 9,743,872 B2
Filed 02/04/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor with time lag compensation | ||
Patent #
US 9,770,211 B2
Filed 04/08/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for a fluid sampling device | ||
Patent #
US 9,775,553 B2
Filed 10/01/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Smart messages and alerts for an infusion delivery and management system | ||
Patent #
US 9,782,076 B2
Filed 07/18/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous analyte measurement systems and systems and methods for implanting them | ||
Patent #
US 9,795,326 B2
Filed 07/22/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 9,795,328 B2
Filed 01/06/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,795,334 B2
Filed 07/09/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for providing analyte sensor insertion | ||
Patent #
US 9,795,331 B2
Filed 04/28/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and apparatus for lancet actuation | ||
Patent #
US 9,795,747 B2
Filed 06/02/2011
|
Current Assignee
Pelikan Technologies Inc.
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,797,880 B2
Filed 10/11/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing rolling data in communication systems | ||
Patent #
US 9,801,545 B2
Filed 07/30/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 9,801,571 B2
Filed 09/16/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and apparatus for lancet actuation | ||
Patent #
US 9,802,007 B2
Filed 11/18/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,804,150 B2
Filed 03/24/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor with lag compensation | ||
Patent #
US 9,804,148 B2
Filed 04/29/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Wireless communication authentication for medical monitoring device | ||
Patent #
US 9,812,002 B2
Filed 04/20/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 9,814,416 B2
Filed 12/13/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for a fluid sampling device | ||
Patent #
US 9,820,684 B2
Filed 06/03/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Close proximity communication device and methods | ||
Patent #
US 9,831,985 B2
Filed 09/29/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing calibration of an analyte sensor in an analyte monitoring system | ||
Patent #
US 9,833,181 B2
Filed 07/13/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Body fluid sampling device with capacitive sensor | ||
Patent #
US 9,839,386 B2
Filed 06/12/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and system for dynamically updating calibration parameters for an analyte sensor | ||
Patent #
US 9,839,383 B2
Filed 04/21/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors and methods of use | ||
Patent #
US 9,844,329 B2
Filed 05/06/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,907,502 B2
Filed 12/16/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Analyte monitoring and management device and method to analyze the frequency of user interaction with the device | ||
Patent #
US 9,913,600 B2
Filed 02/23/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 9,931,075 B2
Filed 11/12/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte monitoring and therapy management system accuracy | ||
Patent #
US 9,936,910 B2
Filed 04/25/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Tissue penetration device | ||
Patent #
US 9,937,298 B2
Filed 12/16/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Closed loop control with reference measurement and methods thereof | ||
Patent #
US 9,943,644 B2
Filed 08/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 9,949,639 B2
Filed 06/27/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for determining elapsed sensor life | ||
Patent #
US 9,949,678 B2
Filed 02/16/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte signal processing device and methods | ||
Patent #
US 9,968,302 B2
Filed 04/04/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems | ||
Patent #
US 9,968,306 B2
Filed 10/21/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods | ||
Patent #
US 9,980,669 B2
Filed 11/07/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Coordination of control commands in a medical device system based on synchronization status between devices | ||
Patent #
US 9,987,426 B2
Filed 01/13/2017
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,002,233 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system having an alert | ||
Patent #
US 10,009,244 B2
Filed 10/30/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Clinical variable determination | ||
Patent #
US 10,016,561 B2
Filed 03/15/2013
|
Current Assignee
Tandem Diabetes Care Incorporated
|
Original Assignee
Tandem Diabetes Care Incorporated
|
Device and method for automatic data acquisition and/or detection | ||
Patent #
US 10,022,499 B2
Filed 08/18/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,031,002 B2
Filed 12/02/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Low pain penetrating member | ||
Patent #
US 10,034,628 B2
Filed 12/20/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Original Assignee
Sanofi-Aventis Deutschland GmbH
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 10,039,881 B2
Filed 07/07/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor sensitivity attenuation mitigation | ||
Patent #
US 10,045,739 B2
Filed 03/23/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,045,720 B2
Filed 10/15/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Infusion pump with blood glucose alert delay | ||
Patent #
US 10,052,049 B2
Filed 08/08/2014
|
Current Assignee
Tandem Diabetes Care Incorporated
|
Original Assignee
Tandem Diabetes Care Incorporated
|
Analyte monitoring system and methods of use | ||
Patent #
US 10,082,493 B2
Filed 04/29/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
CLOSE PROXIMITY COMMUNICATION DEVICE AND METHODS | ||
Patent #
US 20180309540A1
Filed 10/24/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 10,111,608 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,119,956 B2
Filed 10/27/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 10,123,752 B2
Filed 11/10/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Mitigating implantable device power drain associated with stalled telemetry sessions | ||
Patent #
US 10,124,182 B2
Filed 03/28/2017
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Dropout detection in continuous analyte monitoring data during data excursions | ||
Patent #
US 10,132,793 B2
Filed 08/20/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical devices and methods | ||
Patent #
US 10,136,816 B2
Filed 08/31/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same | ||
Patent #
US 10,136,845 B2
Filed 03/14/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Mitigating single point failure of devices in an analyte monitoring system and methods thereof | ||
Patent #
US 10,136,847 B2
Filed 08/24/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,143,409 B2
Filed 10/27/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 10,172,518 B2
Filed 04/13/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control system with safety parameters and methods | ||
Patent #
US 10,173,007 B2
Filed 02/13/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 10,178,954 B2
Filed 05/09/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control and signal attenuation detection | ||
Patent #
US 10,188,794 B2
Filed 06/16/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and systems for early signal attenuation detection and processing | ||
Patent #
US 10,194,844 B2
Filed 03/04/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,201,301 B2
Filed 04/18/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing integrated analyte monitoring and infusion system therapy management | ||
Patent #
US 10,206,629 B2
Filed 04/28/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,231,654 B2
Filed 06/23/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US RE47,315 E1
Filed 06/30/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Intelligent medical implant and monitoring system | ||
Patent #
US 10,248,525 B2
Filed 10/10/2017
|
Current Assignee
Bayer Corporation
|
Original Assignee
Bayer Corporation
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,261,069 B2
Filed 10/20/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing calibration of an analyte sensor in an analyte monitoring system | ||
Patent #
US 10,278,630 B2
Filed 11/30/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods for enabling a disabled capability of a medical device | ||
Patent #
US 10,290,208 B2
Filed 10/17/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte sensor insertion | ||
Patent #
US 10,307,091 B2
Filed 10/20/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 10,327,682 B2
Filed 10/20/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control system interface and methods | ||
Patent #
US 10,328,201 B2
Filed 10/30/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for dynamically updating calibration parameters for an analyte sensor | ||
Patent #
US 10,342,469 B2
Filed 12/08/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dropout detection in continuous analyte monitoring data during data excursions | ||
Patent #
US 10,345,291 B2
Filed 11/16/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 10,349,877 B2
Filed 04/03/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Correction factor testing using frequent blood glucose input | ||
Patent #
US 10,357,607 B2
Filed 12/08/2015
|
Current Assignee
Tandem Diabetes Care Incorporated
|
Original Assignee
Tandem Diabetes Care Incorporated
|
System and method for integration of insulin pumps and continuous glucose monitoring | ||
Patent #
US 10,357,606 B2
Filed 03/13/2013
|
Current Assignee
Tandem Diabetes Care Incorporated
|
Original Assignee
Tandem Diabetes Care Incorporated
|
Analyte monitoring system and methods for managing power and noise | ||
Patent #
US 10,429,250 B2
Filed 03/26/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Smart messages and alerts for an infusion delivery and management system | ||
Patent #
US 10,448,834 B2
Filed 10/05/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 10,456,091 B2
Filed 11/05/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor calibration management | ||
Patent #
US 10,463,288 B2
Filed 08/11/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,463,310 B2
Filed 09/07/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,478,108 B2
Filed 02/05/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical devices and methods | ||
Patent #
US 10,492,685 B2
Filed 08/31/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and method for switching between closed loop and open loop control of an ambulatory infusion pump | ||
Patent #
US 10,569,016 B2
Filed 12/29/2016
|
Current Assignee
Tandem Diabetes Care Incorporated
|
Original Assignee
Tandem Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 10,617,296 B2
Filed 01/07/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for automatic data acquisition and/or detection | ||
Patent #
US 10,617,823 B2
Filed 06/27/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,634,662 B2
Filed 11/05/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Mitigating device power drain associated with stalled telemetry sessions | ||
Patent #
US 10,639,487 B2
Filed 11/07/2018
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 10,653,317 B2
Filed 01/10/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,653,344 B2
Filed 11/19/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dropout detection in continuous analyte monitoring data during data excursions | ||
Patent #
US 10,656,139 B2
Filed 07/08/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and devices for analyte monitoring calibration | ||
Patent #
US 10,660,554 B2
Filed 03/08/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Insulin delivery apparatuses capable of bluetooth data transmission | ||
Patent #
US 10,685,749 B2
Filed 12/28/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 10,750,952 B2
Filed 03/26/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 10,772,572 B2
Filed 10/25/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,820,841 B2
Filed 08/09/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and systems for early signal attenuation detection and processing | ||
Patent #
US 10,820,842 B2
Filed 06/18/2020
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous analyte measurement systems and systems and methods for implanting them | ||
Patent #
US 10,827,954 B2
Filed 10/20/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring and management device and method to analyze the frequency of user interaction with the device | ||
Patent #
US 10,856,785 B2
Filed 03/08/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Real time management of data relating to physiological control of glucose levels | ||
Patent #
US 10,872,102 B2
Filed 08/01/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 10,881,355 B2
Filed 06/15/2020
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Techniques for managing heterogenous nodes configured to support a homogeneous communication protocol | ||
Patent #
US 10,897,763 B2
Filed 01/28/2016
|
Current Assignee
Itron Networked Solutions Inc.
|
Original Assignee
Itron Networked Solutions Inc.
|
BROADCAST DATA TRANSMISSION AND DATA PACKET REPEATING TECHNIQUES FOR A WIRELESS MEDICAL DEVICE NETWORK | ||
Patent #
US 20110110281A1
Filed 01/14/2011
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
CODE ENHANCED STAGGERCASTING | ||
Patent #
US 20100254489A1
Filed 11/14/2008
|
Current Assignee
Thomson Licensing
|
Original Assignee
Thomson Licensing
|
Methods of Operating Wireless Communications Devices Including Detecting Times of Receipt of Packets and Related Devices | ||
Patent #
US 20100303185A1
Filed 06/02/2009
|
Current Assignee
Sony Ericsson Mobile Communications USA Incorporated
|
Original Assignee
Sony Ericsson Mobile Communications USA Incorporated
|
System for Providing Blood Glucose Measurements to an Infusion Device | ||
Patent #
US 20090143662A1
Filed 12/12/2008
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
FAST CHANNEL SWITCHING FOR ENCRYPTED MEDIAFLO MOBILE MULTIMEDIA MULTICAST SYSTEM | ||
Patent #
US 20090187946A1
Filed 01/23/2008
|
Current Assignee
Atmel Corporation
|
Original Assignee
Newport Media Inc.
|
Methodology for managing power consumption in master driven time division duplex wireless network | ||
Patent #
US 6,807,159 B1
Filed 10/25/2000
|
Current Assignee
International Business Machines Corporation
|
Original Assignee
International Business Machines Corporation
|
Radio communication method, radio communication system and wireless terminal | ||
Patent #
US 20050163088A1
Filed 01/27/2005
|
Current Assignee
NEC Corporation
|
Original Assignee
NEC Corporation
|
Method for controlling insulin pump through internet | ||
Patent #
US 20040215492A1
Filed 05/24/2004
|
Current Assignee
Soo Bong Choi
|
Original Assignee
Soo Bong Choi
|
Method of and arrangement for minimizing power consumption and data latency of an electro-optical reader in a wireless network | ||
Patent #
US 20030087681A1
Filed 10/25/2002
|
Current Assignee
Symbol Technologies LLC
|
Original Assignee
Symbol Technologies Inc.
|
Beacon assisted hybrid asynchronous wireless communications protocol | ||
Patent #
US 20030114204A1
Filed 12/13/2001
|
Current Assignee
Google Technology Holdings LLC
|
Original Assignee
Motorola Inc.
|
Ambulatory medical apparatus and method using a telemetry system with predefined reception listening periods | ||
Patent #
US 6,585,644 B2
Filed 01/22/2001
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Blood glucose tracking apparatus and methods | ||
Patent #
US 20030176183A1
Filed 03/29/2002
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Therasense Incorporated
|
Wireless system protocol for telemetry monitoring | ||
Patent #
US 6,441,747 B1
Filed 04/18/2000
|
Current Assignee
LifeSync Corporation
|
Original Assignee
Motorola Inc.
|
Power consumption reduction in medical devices employing just-in-time clock | ||
Patent #
US 6,167,303 A
Filed 04/09/1999
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Method of saving power consumption in a battery operated pager receiver | ||
Patent #
US 5,566,081 A
Filed 10/25/1993
|
Current Assignee
NEC Corporation
|
Original Assignee
NEC Corporation
|
23 Claims
-
1. A method for wireless transmission of data between components of a blood glucose system including a master controller having a receiver and a transmitter, and a slave device comprising an insulin dispensing means and having a receiver and a transmitter, the method comprises the following steps:
-
operating the slave device normally in a power saving mode in which its receiver is activated intermittently at a receiver activation frequency, with the receiver each time being activated for a predetermined listening period and the receiver being deactivated for the rest of the time, activating the transmitter of the controller for a transmission period to transmit a communication initiation data frame including a preamble portion which is chosen such that a preamble signal is transmitted for a preamble period, and subsequently activating the receiver of the controller for a response period, and in case the slave device receives the preamble signal during a listening period, a) maintaining the receiver of the slave device active until at least a portion of the remainder of the communication initiation data frame has been received, b) switching the slave device to a communication mode in which the transmitter of the slave device is activated to transmit a response to the controller, and c) switching the slave device from the communication mode to the power saving mode, initially setting the receiver activation frequency to a first frequency value upon switching from communication mode to power saving mode, and setting the receiver activation frequency to a second frequency value smaller than the first frequency value if no communication initiation data frame is received for a predetermined power saving timeout period, wherein the communication initiation data frame is transmitted such that the preamble period exceeds the length of the cycle duration corresponding to the first frequency value, and, in case no response is received by the controller during the response period, the communication initiation data frame is adapted and retransmitted such that the preamble period is increased and exceeds the length of the cycle duration corresponding to the second frequency value. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. A blood glucose system comprising
a master controller having a receiver, a transmitter and a control means, wherein the control means is operable to activate the transmitter for a transmission period in order to transmit a communication initiation data frame including a preamble portion such that a preamble signal is transmitted for a preamble period, and to subsequently activate the receiver for a response period, a slave device comprising an insulin dispensing means and having a receiver, a transmitter and a control means, wherein the slave device is adapted to be worn on or to be implanted subcutaneously into the body of a patient such that insulin can be delivered from the slave device to the body of the patient, wherein the control means of the slave device is adapted to operate the slave device normally in a power saving mode in which the control means activates the receiver intermittently at a receiver activation frequency, with the receiver each time being activated for a predetermined listening period and the receiver being deactivated for the rest of the time, and wherein the control means of the slave device is further adapted to determine whether the receiver of the slave device receives the preamble signal during a listening period, and in case the preamble signal is received to a) maintain the receiver of the slave device active until at least a portion of the remainder of the communication initiation data frame has been received, b) switch the slave device to a communication mode in which the control means activates the transmitter of the slave device to transmit a response to the controller, and c) subsequently switch the slave device from the communication mode to the power saving mode, wherein the control means of the slave device is adapted to initially set the activation frequency to a first frequency value upon switching the slave device from communication mode to power saving mode, and to set the activation frequency to a second frequency value smaller than the first frequency value if the receiver does not receive a communication initiation data frame for a predetermined power saving timeout period, wherein the control means of the controller is adapted to effect transmission the communication initiation data frame such that the preamble period exceeds the length of the cycle duration corresponding to the first frequency value, and, in case no response is received during the response period, to adapt and retransmit the communication initiation data frame such that the preamble period is increased and exceeds the length of the cycle duration corresponding to the second frequency value.
1 Specification
The present invention relates to a method for wireless transmission of data between components of a blood glucose system including a master controller and a slave device comprising an insulin dispensing means, and to a corresponding blood glucose system.
Diabetes mellitus is a chronic metabolic disorder caused by an inability of the pancreas to produce sufficient amounts of the hormone insulin so that the metabolism is unable to provide for the proper absorption of sugar and starch. This failure leads to hyperglycemia, i.e. the presence of an excessive amount of glucose within the blood plasma. Persistent hyperglycemia causes a variety of serious symptoms and life threatening long term complications such as dehydration, ketoacidosis, diabetic coma, cardiovascular diseases, chronic renal failure, retinal damage and nerve damages with the risk of amputation of extremities. Because healing is not yet possible, a permanent therapy is necessary which provides constant glycemic control in order to always maintain the level of blood glucose within normal limits. Such glycemic control is achieved by regularly supplying external insulin to the body of the patient to thereby reduce the elevated levels of blood glucose.
External insulin was commonly administered by means of typically one or two injections of a mixture of rapid and intermediate acting insulin per day via a hypodermic syringe. While this treatment does not require the frequent estimation of blood glucose, it has been found that the degree of glycemic control achievable in this way is suboptimal because the delivery is unlike physiological insulin production, according to which insulin enters the bloodstream at a lower rate and over a more extended period of time. Improved glycemic control may be achieved by the so-called intensive insulinotherapy which is based on multiple daily injections, including one or two injections per day of long acting insulin for providing basal insulin and additional injections of rapidly acting insulin before each meal in an amount proportional to the size of the meal. Although traditional syringes have at least partly been replaced by insulin pens, the frequent injections are nevertheless very inconvenient for the patient.
Substantial improvements in diabetes therapy have been achieved by the development of blood glucose systems relieving the patient of the daily use of syringes or insulin pens. Such blood glucose systems usually comprise a battery-operated insulin pump and a separate battery-operated control unit. The insulin pump allows for the delivery of insulin in a more physiological manner and can be controlled to follow standard or individually modified protocols to give the patient a better glycemic control over the course of a day. It can be constructed as an implantable device for subcutaneous arrangement or can be constructed as an external device that is carried on the body of the patient.
The operation of the insulin pump can be controlled and modified by means of the control unit. For example, delivery of suitable amounts of insulin by the insulin pump requires that the patient frequently determines his or her blood glucose level and inputs this value into the control unit, which then calculates a suitable modification to the default or currently in use insulin delivery protocol, i.e. dosage and timing, and subsequently communicates with the insulin pump to adjust its operation accordingly. The determination of blood glucose concentration is performed by means of a suitable battery-operated measuring device such as a hand-held electronic meter which receive blood samples via enzyme-based test strips and calculates the blood glucose value based on the enzymatic reaction. Advantageously, the measuring device is an integral part of the blood glucose system, so that the measured value is automatically delivered to the control unit. In this regard, the measuring device may be integrated into the housing of the control unit or may be provided as a separate device communicating with the control unit. Further, it may be necessary to use the control unit each time the patient eats to instruct the pump to administer a specified amount of insulin to cover that meal. Recently, a more or less closed-loop control has been realized in which the control unit modifies the insulin delivery protocol automatically.
In view of the permanence of the therapy, it is desirable to provide the diabetic patient with flexibility, convenience and ease of use in order to increase the quality of his or her life. In this regard, it is evident that cable connections between the individual devices of a blood glucose system are disadvantageous. Thus, it is known to provide a wireless communication link. However, when implementing wireless communication, it has to be taken into account that the necessary receivers and transmitters are a main source of energy consumption. Thus, their use results in reduced battery life and necessitates a more frequent replacement or recharge of the batteries of the individual devices. In medical devices, this issue is not only inconvenient to the patient but also increases the danger of the devices not working properly when needed. Further, for implantable devices the replacement or recharge of the battery is accompanied by surgery. Therefore, it is important to provide for an efficient usage of the transmitters and receivers.
One possibility to reduce the energy consumption is the reduction of transmitting power. However, in many applications this is not sufficient. Therefore, the receivers and transmitters are commonly only activated regularly from time to time during distinct spaced listening and transmission periods, and synchronization means are provided which seek to maintain coincidence between the listening and transmission periods. With regard to battery life, it is desirable to reduce the duration of the individual listening and transmission periods and to increase the spacing between each two successive periods. Due to the spaced listening periods, it is, however, no longer possible to transmit a message immediately upon request. Rather, a device wishing to transmit a message to a particular recipient has to wait at least until the start of the next listening period of the recipient, and has further to wait for a confirmation of receipt at least until its own subsequent listening interval. Therefore, extended periods during which the receivers are deactivated have the disadvantage that they tend to result in substantial delay times which are inconvenient to the patient. Thus, there is a lower limit below which the spacing between successive listening periods should not fall if a suitable compromise between battery life and delay time is to be achieved.
One exemplary blood glucose system operating in this way is described in U.S. Pat. No. 6,585,644. This reference discloses a battery-operated external communication device that wirelessly communicates with at least one battery-operated medical device such as an implantable insulin pump and/or a blood glucose sensor via telemetry messages. The corresponding communication protocol is designed for low power consumption, in particular of the medical device(s), as well as for low communication delay times. According to the protocol, in all devices the receiver is activated only during distinct listening periods separated by periods of inactivity. The length of the listening periods determines the energy consumption, and the spacing between successive listening periods determines the delay time. The telemetry messages include a preamble portion which effects the transmission of a preamble signal upon transmission of the message. Transmission of telemetry messages occurs in corresponding transmission periods between which the transmitter is deactivated. The devices seek to stay synchronized with respect to each other such that the transmission and listening periods coincide. In case of failure of communication or loss of synchronization, the transmission periods may be extended or shifted, or the preamble signal may be transmitted over an extended period of time in order to catch a listening period of the target device. The implantable medical device may have a storage mode to which it can be shifted during periods of non-use and in which the spacing between successive listening periods is substantially increased to conserve battery power. This system has the disadvantages indicated above. It is still desirable to decrease the delay time further without substantially increasing energy consumption.
U.S. Pat. No. 6,807,159 discloses a protocol designed to reduce power consumption in master driven wireless networks without substantially increasing the delay time. The master regularly transmits a polling message to the slave devices which only activate their receiver during the transmission of this message. For each slave device, a probability based approach is used in order to predict the arrival time of the next data packet. The result of this prediction is then used to adjust the polling interval for each slave device. This adaptive probability based polling interval mechanism can lead to an optimization with respect to battery life and delay time if the time distribution of the traffic at each device is approximately constant. However, the mechanism cannot be applied advantageously to wireless blood glucose systems in which communication between the controller and the other devices of the system takes place only from time to time, so that the traffic distribution is highly non-uniform.
It is the object of the present invention to provide a method for wireless transmission of data between components of a blood glucose system that combines a low power consumption of all components of the system with low delay times and that remedies the disadvantages found in the prior art, and to provide a corresponding blood glucose system.
This object is achieved by a method with the features of claim 1 and by a blood glucose system with the features of claim 13. Further preferred embodiments of the invention are the subject-matter of the respective dependent claims.
The steps of the method of the present invention are performed by the components of a blood glucose system that includes an insulin dispensing device and a separate remote controller in order to wirelessly transfer commands, statuses and other data between the individual devices of the system. The data stream between the devices follows the master-slave-principle, wherein the remote controller is the master and the insulin dispensing device and possible further devices are slaves which in the usual manner never initiate a communication but only respond to messages received from the remote controller, i.e. only the master has the right to initiate a communication cycle, whereas the slave devices only transmit when requested by the master to ensure that two slave devices can never occupy the air interface at the same time. Each of the devices of the blood glucose system includes a receiver and a transmitter for wireless receipt and transmission, respectively, of messages.
The insulin dispensing device normally operates in a power saving mode in which its receiver is activated intermittently at a receiver activation frequency, with the receiver each time being activated for a predetermined listening period and the receiver being deactivated for the rest of the time. In a preferred embodiment, the predetermined listening period can e.g. be 10 ms. In case it is intended to use the controller to transmit data to the insulin dispensing device or to request a response from the insulin dispensing device, the transmitter of the controller is activated for a transmission period to transmit a suitable data frame addressed to or intended for the insulin dispensing device. Obviously, apart from the cases in which the blood glucose system does not include a further slave device in addition to the insulin dispensing device or in which it is intended to transmit the data frame to all slave devices of the blood glucose system, the data frame preferably includes an indication that the data frame is addressed to the insulin dispensing device. The data frame includes a preamble portion which is adapted such that upon transmission of the data frame a preamble signal is transmitted for a preamble period. All or some of the data frames may be communication initiation data frames. This type of data frame is transmitted by the controller if it wishes to establish communication with the insulin dispensing device. Following transmission of the communication initiation data frame, the transmitter of the controller is deactivated, and then the receiver of the controller is activated for a response period. In a preferred embodiment, the response period can e.g. be 50 ms to 500 ms and preferably about 100 ms. In any case, the chosen response period must sufficiently exceed the command processing times of the slave devices and must be sufficiently short to meet the desired performance and responsiveness requirements. In case the slave device receives the preamble signal, i.e. at least a part of the preamble included in the preamble portion of the communication initiation data frame, during a listening period, the receiver of the insulin dispensing device is maintained active until at least a portion of the remainder of the communication initiation data frame has been received by the insulin dispensing device. Following receipt of a communication initiation data frame addressed to or intended for the insulin dispensing device, the insulin dispensing device is switched into a communication mode in which its transmitter is activated to transmit a response to the controller. This response is likewise constituted by a data frame and, depending on the type of data frame transmitted by the controller, may be a mere confirmation of receipt or may include further data requested by the controller. The response transmitted by the insulin dispensing device following receipt of a communication initiation data frame indicates to the controller that the insulin dispensing device indeed received the communication initiation data frame and switched to communication mode. Subsequently or in a further step, the insulin dispensing device is switched back from the communication mode to the power saving mode.
According to the invention, upon switching back from communication mode to power saving mode the receiver activation frequency is initially set to a first frequency value. If no communication initiation data frame is received by the insulin dispensing device during a predetermined power saving timeout period, the receiver activation frequency is set to a second frequency value smaller than the first frequency value, thereby providing a “high frequency” power saving mode and a “low frequency” power saving mode. On the other hand, if a communication initiation data frame has been received, the insulin dispensing device is switched to communication mode as described above. Thus, every time the insulin dispensing device has received a communication initiation data frame and communicated with the controller, the spacing between successive listening periods is initially chosen such that a very low delay time but a slightly higher energy consumption than usual results. Only after some time without a further communication initiation data frame addressed to or intended for the insulin dispensing device from the controller, the spacing between successive listening periods is chosen such that the delay time is increased and the energy consumption is decreased to its usual power saving value. This two-step process is advantageous for a blood glucose system, because the patient usually only uses the controller a few times a day (and overall communication between the controller and the insulin dispensing device only occurs from time to time), and only during such times, a high delay time is experienced as inconvenient.
It has been realized that most uses of the controller involve a plurality of messages being sent from the controller to the insulin dispensing device within a small period of time, i.e. the communication behavior is highly non-uniform. According to the method of the present invention, the delay time is reduced at each possible beginning of such an interval of high traffic.
In the communication initiation data frames transmitted by the controller, the length of the preamble portion is chosen such that the preamble period exceeds the length of the cycle duration corresponding to the first frequency value. If no response is received during the response period, i.e. in case the insulin dispensing device has apparently not received the preamble signal in one of its listening periods, the length of the preamble portion is increased such that the preamble period exceeds the length of the cycle duration corresponding to the second frequency value, and the communication initiation data frame is retransmitted with this modified preamble portion. Thus, the controller initially transmits the communication initiation data frame such that it is only received if the insulin dispensing device is in the “high frequency” power saving mode or if one of its listening periods happens to overlap with the transmission time of the preamble signal. If the communication initiation data frame is received by the insulin dispensing device, energy is saved because the communication initiation data frame is transmitted with a short preamble period. Only if this communication attempt is not successful, the communication initiation data frame is transmitted such that it is definitely received at the insulin dispensing device operating in the “low frequency” power saving mode.
The method of the present invention provides the advantage that for the particular non-uniform traffic pattern of a blood glucose system, a low energy consumption at both the remote controller and the insulin dispensing device is combined with a low response time of the insulin dispensing device to requests transmitted by the controller.
The method of the present invention can be advantageously applied in case the blood glucose system includes, in addition to the insulin dispensing device, a blood glucose sensing device which is likewise configured as a slave device, and/or possibly one or more other additional slave devices. All slave devices of such a system, i.e. the insulin dispensing device, the blood glucose sensing device and possibly other slave devices, perform the same steps as described above for the insulin dispensing device. Accordingly, with respect to wireless communication, the slave devices show an identical behavior, i.e. follow the same communication protocol.
In the case of a blood glucose system comprising more than one slave device, the controller may transmit data to a particular slave device or request a response from a particular slave device as described above for the insulin dispensing device, i.e. by activating the transmitter of the controller for a transmission period to transmit a suitable data frame addressed to this slave device. It is then preferred to include an indication of the target slave device for which the communication initiation data frame is intended in the communication initiation data frame transmitted by the controller in order to establish communication with the slave device. Upon receipt of the preamble signal by a slave device during one of its listening periods, its receiver is maintained active until the target device indication included in the communication initiation data frame has been received. At this point, it can be determined whether the communication initiation data frame is addressed to this slave device. Only if the communication initiation data frame is indeed addressed to this slave device, its receiver is maintained active until the remainder of the communication initiation data frame has been received and the slave device is switched into communication mode as described above. Otherwise, the slave device is maintained in the power saving mode. However, the activation frequency for the slave device is changed to a third frequency value greater than the second frequency value, and only if no communication initiation data frame is received for a predetermined timeout period, which may e.g. be identical to the above predetermined power saving timeout period, the activation frequency is changed back to the second frequency value. Thus, whenever a communication initiation data frame is received, a slave device reduces the delay time even if the communication initiation data frame is addressed to another slave device. This behavior is advantageous because it has been found that during any period of high traffic the controller will most likely not only communicate with one slave device but with all slave devices in turn. Preferably, the third frequency value and the first frequency value are chosen to be identical.
In a preferred embodiment, the first frequency value is chosen such that the receiver of the insulin dispensing device is activated every 100 to 500 ms, preferably every 300 ms, and the second frequency value is chosen such that the receiver of the insulin dispensing device is activated every 0.5 to 30 s, preferably every 2 to 20 s and most preferably about every 3 s. In this regard, it is advantageous if the activation period corresponding to the second frequency value is an integral multiple of the activation period corresponding to the first frequency value. It is evident that the frequency values are always a compromise between suitable response times and sufficiently low energy consumption and have to be chosen to meet the particular requirements. On the one hand, higher frequency values increase the energy consumption of the slave devices, but reduce the energy consumption of the controller because shorter preamble periods may be utilized. On the other hand, lower frequency values reduce the energy consumption of the slave devices, but result in longer delay times and, due to longer preamble periods being necessary, in an increased energy consumption of the controller. Further, the short and the long preamble periods utilized by the controller are preferably chosen such that they exceed the time period of the “high frequency” power saving mode and the “low frequency” power saving mode, respectively, by about 25 ms. Thus, in the most preferred embodiment, the preamble periods are approximately 325 ms and approximately 3025 ms, respectively. Further, it is preferred that the predetermined power saving timeout period is 10 s to 60 s and preferably about 15 s. The optimum value of the predetermined power saving timeout period for a particular application should be chosen on the one hand based on an estimation of the average time period between different user actions on the controller that require wireless communication, and on the other hand on an estimation of the time after which the user may be considered not to seek to invoke another user interaction requiring wireless communication. The above values for the various parameters result in a good balance between low energy consumption and low response time of the blood glucose system.
In the case of more than one slave device, it may be advantageous in some instances if the above method is modified such that, upon switching of a slave device from communication mode to power saving mode, the receiver activation frequency is immediately set to the second frequency value without first setting it to the first frequency value. This modified method can be advantageous if in all probability the controller polls each slave device exactly once during each communication period. In such a case, an additional power saving can be achieved on the side of the slave devices.
The method may involve that all data frames transmitted by the controller are communication initiation data frames. However, it is preferred that following transmission of a communication initiation data frame the controller also sends further data frames. Thus, in a preferred version of the method of the present invention, following transmission of a communication initiation data frame, the transmitter of the controller is activated for at least one further transmission period to transmit at least one further data frame addressed to or intended for the same slave device and including a preamble portion which is chosen such that the preamble signal is transmitted for a preamble period, and following transmission of each of the least one further data frame the receiver of the controller is activated for a response period, which in a preferred embodiment can be e.g. 50 ms to 500 ms, preferably about 100 ms. In order to provide a possibility for the slave devices to distinguish communication initiation data frames from further data frames and possibly to distinguish between different types of further data frames, all data frames transmitted by the controller include a command portion in which a command is included that identifies the content of the data frame. For any communication initiation data frame, a communication initiation command is included in the respective command portion to identify this data frame as a communication initiation data frame.
In case a slave device receives the preamble signal during a listening period while it is in the power saving mode, the receiver of the slave device is maintained active at least until the command included in the command portion of the data frame has been received, and the slave device is maintained in the power saving mode in case the command is not the communication initiation command. On the other hand, in case a slave device receives the preamble signal while it is in the communication mode, the receiver of the slave device is maintained active at least until the command included in the command portion of the data frame has been received. If the command is not the communication initiation command and the slave device is the intended recipient of the data frame, the receiver of the slave device is maintained active until the remainder of the data frame has been received, and then the transmitter of the slave device is activated and deactivated to transmit a response to the controller. Thus, the slave devices only respond to further data frames if they are already in communication mode. It should be noted that each slave device transmits a response upon receipt of the communication initiation data frame instructing this slave device to switch to communication mode, i.e. the communication initiation data frame starting a communication cycle, as well as upon receipt of any further data frame addressed to this slave device and received by this slave device when it is still in communication mode. Therefore, in each communication cycle with a particular slave device, all data frames transmitted by the controller to this slave device entail a response data frame transmitted by the slave device to the controller. Depending on the type of data frame transmitted by the controller, the response data frame may be a mere confirmation of receipt or may include further data requested by the controller.
In a preferred embodiment, the communication mode at a particular slave device is terminated if no communication initiation data frame or further data frame addressed to this slave device is received for a predetermined communication timeout period, and the communication mode is arranged such that the receiver of the respective slave device is maintained active whenever its transmitter is not activated to transmit a response. Thus, starting with the receipt of the communication initiation data frame a particular slave device is maintained in communication mode at least for the predetermined communication timeout period. In communication mode, the delay time is substantially zero as the receiver of the slave device is active all the time, so that efficient communication involving a plurality of further data frames and corresponding responses is achieved. In this way, a number of data frames can be transmitted to the slave device with substantially zero delay time. It is further preferred that at the controller the time since transmitting the last data frame to a particular slave device is tracked and that it is determined at the controller, prior to transmitting a further data frame to the same slave device, based on a comparison between the measured time and the predetermined communication timeout period whether this slave device is expected to still be in communication mode. If it is determined that the slave device is expected to still be in communication mode, the controller initially transmits the data frame such that the preamble period spans a time period shorter than the cycle durations corresponding to the first frequency value and the second frequency value. In fact, the preamble period can be chosen to have a minimum duration, such as e.g. about 25 ms, because in communication mode the receiver of the slave device is always activated. In this way, additional energy saving is achieved on the side of the controller. In a preferred embodiment, the predetermined communication timeout period is 0.2 to 2.5 s and preferably approximately 2 s.
In the case of such an extended communication mode, it is further preferred to provide the option of including a delay time period indication into a response transmitted by a slave device to a particular first data frame to indicate that the actual response will be transmitted later. With other words, in case a slave device determines that it cannot transmit a response within the response period following transmission of the data frame, it can indicate to the controller that there will be a delay in the response. Then the transmitter and the receiver of both the slave device and the controller are deactivated for the indicated delay time period. Only after the end of the indicated delay time period, the transmitter of the controller and the receiver of the slave device are activated, so that the controller may transmit a second data frame requesting the delayed response from the slave device and the slave device can receive this request. Upon receipt of the request data frame, the transmitter of the slave device is activated to transmit the requested response to the controller. In this way, the response period can be chosen to be relatively small in order to save energy.
In the case of such an extended communication mode in which a communication cycle involves a communication initiation data frame followed by one or more additional data frames, it is advantageous if the data frames transmitted by the controller and by the slave device(s) include a frame number or frame reference uniquely identifying the data frame within a particular communication cycle. For example, the communication initiation data frame may include the frame number 1, and the data frame transmitted by the addressed slave device in response to the communication initiation data frame may likewise include the frame number 1. For each additional data frame transmitted by the controller and the corresponding response data frame the frame number is increased by 1, i.e. the first additional data frame and the response data frame have the frame number 2, the second additional data frame and the response data frame have the frame number 3 on so on. In another example, the communication initiation data frame includes the frame number 1, the data frame transmitted by the addressed slave device in response to the communication initiation data frame includes the frame number 2, the first additional data frame transmitted by the controller includes the frame number 3, and so on. In any case, by means of such frame numbers or frame references it can be guaranteed that all commands issued by the controller by means of transmitting corresponding data frames are executed exactly once by the addressed slave device in a predetermined order. The controller knows which frame number or frame reference a response data frame confirming execution of a command must have, so that the controller may reissue the command until execution of the command is confirmed. Further, the slave device knows which frame number or frame reference the additional data frame corresponding to the next command in a sequence of commands must have, so that it may issue a warning in case a command in the sequence is missing, and so that executing a particular command more than once is prevented.
In order to further increase the safety of the blood glucose system, it is also advantageous if each data frame not only includes an indication of the addressed slave device (in case of more than one slave device), but also a source device reference uniquely identifying the device (controller or slave device) that transmitted the data frame. This source device reference may be utilized to ensure that the components of a particular blood glucose system disregard data frames not belonging to this blood glucose system.
In a further preferred embodiment, the controller may transmit a data frame including a termination command to a slave device in communication mode, and the slave device terminates the communication mode upon receipt of this termination data frame. Thus, in case it is not intended to use the controller to transmit a further data frame to a slave device in communication mode, the communication mode involving a substantially permanently activated receiver may be terminated prior to the end of the communication timeout period in order to save energy. This possibility of terminating the communication mode of a slave device is preferably combined with the above described embodiment in which the communication mode at a particular slave device is terminated if no communication initiation data frame or further data frame addressed to this slave device is received for a predetermined communication timeout period. It is then preferred that the communication mode should always be terminated by means of a termination command, and that the communication timeout period is only provided as a safety feature to avoid that in case of errors a slave device inadvertently remains in communication mode permanently.
It is further preferred that the transmission of at least one communication initiation data frame by the controller is initiated by user request, i.e. the communication initiation data frame is transmitted without waiting for some predetermined transmission window. This may be the case if the patient decides to modify the insulin delivery protocol or to change some other setting of a slave device, or if the patient needs to dispense insulin prior to a meal.
Additionally or alternatively, it is preferred that a timer event is periodically generated in the controller and that a communication initiation data frame is transmitted by the controller upon each occurrence of such a timer event. In this regard, it is particularly advantageous to choose the frequency at which the timer events occur to have the second frequency value or such that the second frequency value is an integral multiple of the timer event frequency, to include a time reference in each communication initiation data frame initiated by a timer event, to examine the time reference upon receipt at a slave device, and to synchronize, based on the time reference, the start times of the listening periods of the slave devices with the timer events. In this way, irrespective of the current activation frequency value of a target slave device, it is ensured that the controller can reach the target slave device using a preamble period that only needs to exceed the length of the cycle duration corresponding to the first frequency value. Thus, energy consumption as well as delay time are reduced. The timer event triggered transmission of a communication initiation data frame or autopolling is utilized e.g. for automatic control and maintenance of the slave devices. Thus, timer event generated communication cycles may serve to periodically check the status of the slave devices or to control the operation of the slave devices, e.g. to regularly dispense suitable amounts of insulin by means of the insulin dispensing device. Preferably, such timer events are generated every 3 to 5 min, preferably about every 5 min. Further, it may be advantageous if the communication initiation data frames transmitted upon occurrence of a timer event are distinguished from communication initiation data frames initiated by user request, and if the slave device receiving a communication initiation data frame determines whether the communication initiation data frame was initiated by a timer event or by user request. In this way, the communication timeout period, the power saving timeout period and/or the timeout period utilized by slave devices not addressed by a communication initiation data frame to determine when to change from “high frequency” power saving mode to “low frequency” power saving mode may be chosen to be shorter for a communication initiation data frame initiated by a timer event than for a communication initiation data frame initiated by user request. This can be advantageous, because in most instances autopolling does not require extended communication and because autopolling does not require user interaction so that extended delay times do not lead to user annoyance.
The present invention further relates to a blood glucose system implementing the method of the present invention. Such a system comprises a master controller having a receiver, a transmitter and a control means, wherein the control means is operable to activate the transmitter for a transmission period in order to transmit a communication initiation data frame including a preamble portion such that a preamble signal is transmitted for a preamble period, and to subsequently activate the receiver for a response period. The system further includes a slave device comprising an insulin dispensing means and having a receiver, a transmitter and a control means, wherein the slave device is adapted to be worn on or to be implanted subcutaneously into the body of a patient such that insulin can be delivered from the slave device to the body of the patient. The control means of the slave device is adapted to operate the slave device normally in a power saving mode in which the control means activates the receiver intermittently at a receiver activation frequency, with the receiver each time being activated for a predetermined listening period of e.g. 10 ms and the receiver being deactivated for the rest of the time. The control means of the slave device is further adapted to determine whether the receiver of the slave device receives the preamble signal of the communication initiation data frame during a listening period, and in case the preamble signal is received to maintain the receiver of the slave device active until at least a portion of the remainder of the communication initiation data frame has been received, switch the slave device to a communication mode in which the control means activates the transmitter of the slave device to transmit a response to the controller, and subsequently switch the slave device from the communication mode to the power saving mode. The response transmitted by the insulin dispensing device following receipt of a communication initiation data frame indicates to the controller that the insulin dispensing device indeed received the communication initiation data frame and switched to communication mode.
According to the present invention the control means of the slave device is adapted to initially set the activation frequency to a first frequency value upon switching the slave device from communication mode to power saving mode, and to set the activation frequency to a second frequency value smaller than the first frequency value if the receiver does not receive a communication initiation data frame intended for the slave device for a predetermined power saving timeout period, wherein the control means of the controller is adapted to transmit the communication initiation data frame such that the preamble period exceeds the length of the cycle duration corresponding to the first frequency value, and, in case no response is received during the response period, to adapt and retransmit the communication initiation data frame such that the preamble period is increased and exceeds the length of the cycle duration corresponding to the second frequency value.
In a preferred embodiment, the first frequency value is chosen such that the receiver of the slave device is activated every 100 to 500 ms, preferably every 300 ms, and the second frequency value is chosen such that the receiver of the slave device is activated every 0.5 to 30 s, preferably every 2 to 20 and most preferably about every 3 s. Further, the short and the long preamble periods utilized by the controller are preferably chosen such that they exceed the time period of the “high frequency” power saving mode and the “low frequency” power saving mode, respectively, by about 25 ms. Thus, in the most preferred embodiment, the preamble periods are approximately 325 ms and approximately 3025 ms, respectively. Further, it is preferred that the predetermined power saving timeout period is 10 s to 60 s and preferably about 15 s. These values result in a good balance between low energy consumption and low response time of the blood glucose system.
In a preferred embodiment, the system includes at least one further slave device, at least one of which comprises a blood glucose sensing means, wherein all slave devices comprise a receiver, a transmitter and a control means configured in the same way as the receiver, the transmitter and the control means, respectively, of the slave device comprising an insulin dispensing means. The control means of the controller is further adapted to include an indication of a target slave device in each communication initiation data frame in order to individually address the various slave devices. The control means of the slave devices is further adapted to maintain the receiver of the slave device active at least until the receiver has received the target device indication, and maintain the receiver of the slave device active until the remainder of the communication initiation data frame has been received and switch the slave device into communication mode if the slave device is the target slave device, or, in case the slave device is not the target device, maintain the slave device in the power saving mode, and set the receiver activation frequency for the slave device to a third frequency value, which is greater than the second frequency value and is preferably identical to the first frequency value and subsequently set the receiver activation frequency to the second frequency value if the receiver does not receive a communication initiation data frame for a predetermined timeout period, in case the control means determines that the slave device receives the preamble signal during a listening period.
It is further preferred that following transmission of a communication initiation data frame, the control means of the master controller is further operable to activate the transmitter of the controller for at least one further transmission period to transmit at least one further data frame addressed to or intended for the same slave device and including a preamble portion such that the preamble signal is transmitted for a preamble period, and following transmission of each of the least one further data frame to activate the receiver of the controller for a response period, which can e.g. be 50 ms to 500 ms and preferably about 100 ms, wherein all data frames transmitted by the controller include a command portion in which a command is included. The control means of the controller is further adapted to include a communication initiation command in the command portion of any communication initiation data frame to indicate that this data frame is a communication initiation data frame. The control means of the slave devices is further adapted to determine whether the receiver of the slave device receives the preamble signal during a listening period while it is in the power saving mode, and in case this determination is positive to maintain the receiver of the slave device active until the command included in the command portion of the data frame has been received, and maintain the slave device in the power saving mode in case the command is not the communication initiation command. The control means of the slave devices is further adapted to determine whether the receiver of the slave device receives the preamble signal while it is in the communication mode, and in case this determination is positive to maintain the receiver of the slave device active at least until the command included in the command portion of the data frame has been received, and if the command is not the communication initiation command and the slave device is the intended recipient of the data frame, maintain the receiver of the slave device active until the remainder of the data frame has been received, and activate and deactivate the transmitter of the slave device to transmit a response to the controller. It should be noted that each slave device transmits a response upon receipt of the communication initiation data frame instructing this slave device to switch to communication mode, i.e. the communication initiation data frame starting a communication cycle, as well as upon receipt of any further data frame addressed to this slave device and received by this slave device when it is still in communication mode. Therefore, in each communication cycle with a particular slave device, all data frames transmitted by the controller to this slave device entail a response data frame transmitted by the slave device to the controller. Depending on the type of data frame transmitted by the controller, the response data frame may be a mere confirmation of receipt or may include further data requested by the controller.
In a further preferred embodiment, the control means of each slave device is adapted to terminate the communication mode if the receiver does not receive a data frame for the respective slave device for a predetermined communication timeout period, and to maintain the receiver of the respective slave device active in communication mode whenever it does not activate the transmitter to transmit a response. In a preferred embodiment, the predetermined communication timeout period is 0.2 to 2.5 s and preferably approximately 2 s.
It is also preferred that the controller further includes a timer, and that the control means of the controller is adapted to start the timer upon transmitting a data frame to a particular slave device, to determine, prior to transmitting a data frame to the same slave device, based on a comparison between the current value of the timer and the predetermined communication timeout period whether the slave device is expected to still be in communication mode, and in case it determines that the slave device is expected to still be in communication mode to initially transmit the data frame such that the preamble period spans a time period shorter than the cycle durations corresponding to the first frequency value and the second frequency value.
It is further preferred that the control means of each slave device is adapted to include a delay time period indication into a response transmitted by the slave device to a particular first data frame to indicate that the actual response will be transmitted later, to deactivate the transmitter and the receiver for the indicated delay time period, to activate the receiver of the slave device after the end of the delay time period to wait for the receipt of a second data frame requesting the response to the first data frame, and to subsequently activate the transmitter of the slave device to transmit the requested response to the controller, and that the control means of the controller is adapted to deactivate, upon receipt of a response including a delay time period indication, the transmitter and the receiver of the controller for the indicated delay time period, and to activate the transmitter of the controller after the end of the delay time period to transmit a second data frame requesting the response to the first data frame.
In a preferred embodiment, the control means of the controller is operable to transmit a data frame including a termination command to a slave device in communication mode, and the control means of each slave device is adapted to terminate the communication mode upon receipt of this data frame. This possibility of terminating the communication mode of a slave device is preferably combined with the above described embodiment in which the communication mode at a particular slave device is terminated if no communication initiation data frame or further data frame addressed to this slave device is received for a predetermined communication timeout period. It is then preferred that the communication mode should always be terminated by means of a termination command, and that the communication timeout period is only provided as a safety feature to avoid that in case of errors a slave device inadvertently remains in communication mode permanently.
In a preferred embodiment, the controller comprises an actuation means, actuation of which provides a signal to the control means instructing the control means to transmit a data frame.
It is also preferred that the controller further comprises a timer event generator operable to periodically generate a timer event and to provide corresponding timer event signals to the control means of the controller, and that the control means of the controller is adapted to transmit a communication initiation data frame upon receipt of such a timer event signal. In this case, it is further preferred that the frequency with which the timer event generator generates the timer events has the second frequency value or is such that the second frequency value is an integral multiple of the timer event frequency, the controller comprises a clock and the control means of the controller is adapted to include a time reference derived from the clock in each data frame initiated by the receipt of a timer event signal, and the control means of the slave devices are adapted to examine the time reference upon receipt at a slave device, and to synchronize by means of the time reference the start times of the listening periods with the timer events. Preferably, the timer event generator is able to generate such timer events every 3 to 5 min, preferably about every 5 min.
In a preferred embodiment, the controller includes a blood glucose sensing means. Thus, the system may include a separate blood glucose sensing device configured as slave and/or may include a controller into which a blood glucose sensing device is integrated.
In the following, the invention is explained in more detail for a preferred embodiment with reference to the figures.
In
The insulin pump 3 and the blood glucose measuring device 4 each comprise a housing 13, a display 14 and an antenna 15. Further main components of the of the insulin pump 3 and the measuring device 4 are depicted in the schematic block diagram shown in
In
In the RF wireless network established by the controller 2, 2′ and the devices 3 and 4, the controller 2, 2′ is configured as master and the devices 3 and 4 are configured as slaves, i.e. they never initiate a communication but only respond to commands received from the controller 2, 2′. The controller 2, 2′ and the slave devices 3, 4 communicate by exchanging data frames, wherein each transmission preferably consists of one data frame only. One such data frame 300 is shown schematically in
In
According to the embodiment shown in
In communication mode, the transmitter 18 is activated and deactivated to transmit a response to the controller 2, 2′ (step 209), and then the receiver 19 is again activated (step 210) to wait for further data frames 300 from the controller 2, 2′. The response to the communication initiation data frame indicates to the controller 2, 2′ that the slave device 3, 4 is now in communication mode. In contrast to the sniff mode, the receiver 19 is maintained activated until the preamble signal of a further data frame 300 is detected or until a communication timeout period of e.g. 2 s duration (i.e. longer than the listening period) has elapsed without detection of the preamble signal (step 211). If a preamble signal of a further data frame is detected in step 211, the further data frame is received in step 212. Otherwise, and in case none of the received further data frames are addressed to the slave device, the slave device is switched back to power saving mode (step 214). The same happens if the command contained in the command portion 304 of the further data frame 300 indicates that the communication mode shall be terminated immediately (step 213). However, if the further data frame 300 received in step 212 is not such a termination data frame, the receiver 19 is deactivated in step 214 to go back to step 209 in order to transmit a response. Depending on the command, such response may be a mere confirmation of receipt or may include data requested by the controller 2, 2′. Thus, as long as the controller 2, 2′ continues to transmit further data frames 300 to the same slave device 3, 4 such that the preamble signals of the respective further data frames are received before the communication timeout period has elapsed, the slave device 3, 4 stays in communication mode, in which the receiver 19 is only deactivated during the time it takes to transmit a response. In normal operation, the communication mode is terminated by means of a further data frame 300 including in the command portion 304 a termination command.
Upon switching back from communication mode to power saving mode in step 214, the sniff interval is adjusted to be 300 ms in order to reduce the delay time in the case of a further communication attempt by the controller 2, 2′. The same is done in step 216, when a slave device 3, 4 receives a data frame 300 including the communication initiation command in the command portion 304, and determines in step 206 that the address contained in the address portion 303 is not its own address.
In any case, following receipt of a data frame 300 which is either not a communication initiation data frame (step 205) or is a communication initiation data frame addressed to a different device (step 206), the receiver 19 is deactivated for the rest of the sniff interval in step 217. Subsequently, it is determined in step 218 whether the sniff interval is currently 300 ms and whether a predetermined power saving timeout period of e.g. 15 s has elapsed since the sniff interval was last set to 300 ms. Before the end of this timeout period, the sniff interval is left unchanged. If it has elapsed, the sniff interval is changed to its normal value of 3 s in step 219. In this way, as soon as the controller 2, 2′ initiates communication with one of its slave devices 3, 4 the delay time is reduced for all of these devices 3, 4, thereby increasing the efficiency of communication in the blood glucose system 1, 1′ with its highly non-uniform traffic distribution on the air interface.
With the slave devices 3, 4 operating in this manner, in case communication between the controller 2, 2′ and one of the devices 3, 4 is desired, a data frame 300 is prepared in the controller 2, 2′ in step 100 (
After receipt of a response, it is ensured that the respective slave device 3, 4 is in communication mode with its receiver 19 activated. In this situation, a further data frame 300 is prepared (step 110), and in step 111 the address of the slave device 3, 4 is included in the address portion 303, a suitable command is included in the command portion 304 and optionally additional data are included in data portion 305. The control electronics 12 in combination with the clock 23 always track the time since transmitting the last data frame to the current slave device, and in step 112 the control electronics 12 compare this time with the communication timeout period in order to determine whether the slave device is still in communication mode. If it is determined that the current slave device 3, 4 is still in communication mode, the preamble period is set to 25 ms in step 114. This minimal preamble period is sufficient since the target slave device is in communication mode so that its receiver 19 is activated. However, it is necessary to transmit the further data frames timely enough for the slave device to still be in communication mode, i.e. the time interval between successive data frames must be smaller than the communication timeout period. Otherwise, if the above determination is negative, the controller goes back to step 100 to initiate another communication cycle with the slave device (step 113). Then, the further data frame 300 is transmitted in step 115, followed by activating the receiver 9 for 100 ms to wait for a response (step 116). Thus, the target slave has to respond within 100 ms of receipt of a data frame. If the controller 2, 2′ does not receive a response within this response time (step 117), it goes back to step 115 in order to retransmit the further data frame. If it is determined that further commands shall be transmitted to the same slave device (step 118), another further data frame 300 is prepared in step 110. Otherwise, a data frame 300 including a termination command in its command portion 304 is prepared and transmitted to the slave device in step 119 in order to effect its switching back to power saving mode.
In certain cases, a slave device 3, 4, which just has received a further data frame from the controller 2, 2′, may not be able to transmit a response within the response time period of the controller 2, 2′. For example, if the further data frame includes a command requesting the slave device 3, 4 to collect data and provide these data to the controller 2, 2′, the necessary data may not be available immediately. In such situations, the slave device 3, 4 has the possibility of delaying transmission of the response in step 209 and to perform the steps of
In order for this delay mechanism to work properly, the controller 2, 2′ does not only determine whether a response has been received in step 117, but the control electronics 12 further examine the received response to determine whether it includes a delay time indication (which could e.g. be represented by a suitable command and additional data specifying the delay time period). If no delay time indication is found, the method proceeds to step 118 (step 511). On the other hand, in case a delay time indication is found, the control electronics 12 effect deactivation of the receiver 10 and the transmitter 9 for the corresponding delay time period (step 512) in order to save energy. After the delay time period has elapsed (as determined by the control electronics 12 in combination with the clock 23), the control electronics 12 prepare a further data frame (step 513), include a target device indication (step 514), and include a request command and additional data requesting the target slave device to transmit a response to a particular earlier data frame (step 515). Then, the preamble period is set to 25 ms in step 516 (which is sufficient because the target slave device has activated its receiver after the delay time period has elapsed), and the request data frame is transmitted in step 517. Finally, the method proceeds to step 116 (step 518) to wait for the requested response.